Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790782 | 0.73 | ESR1 (0.42) | HSD17B10ALDH1A1TDP1HPGDCYP3A4 | |
| SCHEMBL24030 | 0.71 | GPR3 (0.46) | HSD17B10ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL144610 | 0.68 | HSD17B10 (0.46) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL1869260 | 0.68 | GPR3 (0.54) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL159417 | 0.67 | KDM4E (0.63) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL2514493 | 0.65 | GPR3 (0.34) | HSD17B10ALDH1A1HPGDCYP3A4CASP1 | |
| SCHEMBL29613365 | 0.65 | HSD17B10 (0.72) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL535472 | 0.65 | HSD17B10 (0.72) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL29388002 | 0.65 | HSD17B10 (0.69) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL30374792 | 0.65 | HSD17B10 (0.69) | HSD17B10ALDH1A1TSHRTDP1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220190296-A1 | LIGHT-EMITTING DEVICE AND AN ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-06-16 | — | — | US | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| US-20240231224-A9 | HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF | LAM RESEARCH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024137876-A2 | SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS | TWELVE BENEFIT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240200208-A1 | CO2 PURIFICATION AND REDUCTION SYSTEMS | SUMITOMO MITSUI BANKING CORPORATION | 2024-06-20 | — | — | US | disclosed |
| US-20240192590-A1 | APPARATUS AND PROCESS FOR EUV DRY RESIST SENSITIZATION BY GAS PHASE INFUSION OF A SENSITIZER | LAM RESEARCH CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024123514-A1 | CO2 PURIFICATION AND REDUCTION SYSTEMS | TWELVE BENEFIT CORPORATION (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-118159909-A | Gray tone resist and processing | 元平台技术有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024108304-A1 | DITHIOL CHELATORS FOR METAL CONJUGATION TO ANTIBODIES | STANDARD BIOTOOLS CANADA INC. (CA) | 2024-05-30 | — | — | WO | disclosed |
| US-20240134274-A1 | HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF | LAM RES CORP (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050043541-A1 | Metal complexes useful in metathesis and other reactions | RIMTEC CORPORATION (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | disclosed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | disclosed |
| EP-1044197-A2 | NEW PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043541-A1 | Metal complexes useful in metathesis and other reactions | TST, ETFA, TTPA | HSD17B10 1432/4885ALDH1A1 214/4885TSHR 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.